Sökning: "177Lu-octreotate therapy"

Visar resultat 1 - 5 av 11 avhandlingar innehållade orden 177Lu-octreotate therapy.

  1. 1. Dosimetry of Radionuclide Therapy with 177Lu-octreotate

    Författare :Mattias Sandström; Hans Lundqvist; Mark Lubberink; Sven-Erik Strand; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; 177Lu-octreotate; Absorbed dose; Neuroendocrine tumour; Medicinsk radiofysik; Medical Radiophysics;

    Sammanfattning : In radionuclide therapy it is still common to administer standard activities or to scale administered activity with blunt parameters such as body weight or surface area. This is not ideal because, due to considerable variation in kinetics, large safety margins have to be applied to avoid radiation damage to healthy organs, which causes under-treatment of many patients. LÄS MER

  3. 2. Multiparametric MRI for evaluation of tumour treatment response : Studies of 177Lu-octreotate therapy of neuroendocrine tumour

    Författare :Mikael Montelius; Göteborgs universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Cancer; Functional imaging; IVIM; MRI; DWI; DCE; histology; 177Lu-octreotate; small intestine neuroendocrine tumour; NET; diffusion; perfusion; semi-quantitative; proteomics; ionizing radiation; biology; imaging biomarker;

    Sammanfattning : Clinical assessment of tumour response to treatment largely relies on estimates of tumour size by, e.g., measuring the largest tumour diameters on magnetic resonance (MR) or computed tomography (CT) images, weeks or months after treatment. LÄS MER

  4. 3. Strategies for optimisation of 177Lu-octreotate therapy – exploring local administration and combination therapy regimens

    Författare :Viktor Sandblom; Göteborgs universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Peptide receptor radionuclide therapy; PRRT; 177Lu-octreotate; Neuroendocrine tumours; Optimisation; Local administration; Combination therapy;

    Sammanfattning : Neuroendocrine tumours (NETs) are a group of heterogeneous tumour types that originate in hormone-producing organs. Patients with NETs are often diagnosed after the primary tumour has metastasised. LÄS MER

  5. 4. Therapy of neuroendocrine tumors with 177Lu-octreotate - Human tumor cell types and models and optimization of treatment : Terapi av neuroendokrina tumörer med 177Lu-octreotate

    Författare :Johanna Dalmo; Göteborgs universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; somatostatin; radionuclide therapy; receptor up-regulation; RBP; nephrotoxicity;

    Sammanfattning : Neuroendocrine (NE) tumors (NET) have often metastasized at the time of diagnose, which makes it hard to cure patients with NET. Radiolabeled hormone analogues (especially somatostatin analogues, SS) can be used for diagnostics (e.g. 111In-octreotide) and therapy (e. LÄS MER

  7. 5. Therapy with 177Lu-octreotate - pharmacokinetics, dosimetry and kidney toxicity

    Författare :Maria Larsson; Göteborgs universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; PRRT; 177Lu-octreotate; 111In-octreotide; dosimetry; biokinetics; scintigraphy; conjugate view method; renal function; renal toxicity; lysine; DMSA; 99mTc-DTPA; 99mTc-DMSA;

    Sammanfattning : 177Lu-octreotate is used for treatment of patients with somatostatin receptor expressing neuroendocrine tumors in some clinics using a standard schedule. Renal and bone marrow toxicity are the main limiting factors. LÄS MER